 Athenex Inc NASDAQ: ATNX held a Type A meeting with the FDA during the second quarter of 2021 to discuss the deficiencies raised in the Complete Response Letter CRL regarding application for oral paclitaxel plus encequidar to treat metastatic breast cancer. At the meeting, Athenex provided additional analyses, including overall survival data on patient subgroups, to provide a more comprehensive summary of the riskbenefit assessment. 